Havas Health named Anna Maria Marra as CEO of Europe on Tuesday morning, a role in which she will lead and oversee all ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

Both the FDA and EMA previously granted fast track and orphan drug designations to VCN-01 for the treatment ... Placed second of five finalists for Merck KGaA's EMEA Advance Biotech Grant which ...

The drug, a fixed-dose combination based on established antibiotic Primaxin (imipenem/cilastatin) with Merck’s novel beta-lactamase inhibitor relebactam, was first approved by the FDA for ...

Italy has awarded Boston University’s CARB-X (Combating Antibiotic-Resistant Bacteria ... Alto Neuroscience said an experimental drug failed to improve depression symptoms in a mid-stage clinical ...

The global necrotizing fasciitis treatment market is poised for significant growth, with a projected valuation of USD 2.9 billion in 2024 and an anticipated increase to USD 4.5 billion by the end of ...

Acurx Pharmaceuticals is undervalued, with promising market potential for its lead antibiotic, ibezapolstat, targeting C. difficile infections, a billion-dollar opportunity. Ibezapolstat's Phase 2 ...

Some companies are still plugging away at antibiotics R&D, but aside from some exceptions such as GlaxoSmithKline, AstraZeneca and Merck ... that there are too few drugs in development to meet ...

Application error: a client-side exception has occurred (see the browser console for more information).

The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat certain ... the health regulator said on Friday. Merck has acquired Modifi Biosciences for as ...